Abstract: Objective To clarify the characteristics of HBV resistance mutant induced by treatment of chronic hepatitis B with nucleos(t)ide analogues (NAs).Methods HBV DNA genotyping and drug resistance mutant detection were performed in 211 patients with chronic hepatitis B (CHB) treated with NAs and 195 NA-naïve patients with CHB via DNA chip technology which combines routine PCR and DNA reverse spot hybridization, and the characteristics of NAs resistance mutation was analyzed.Result sAmong the 406 samples, 61% were genotype B, 31% were genotype C, and the mutation rate of genotype C(65%) was significantly higher than that of genotype B(46%) (P<0.001). rtM204I was the most common resistance mutation site (43%). rtM204V, rtL180M, rtM250V, rtA181T/V, rtN236T and rtM250L were often accompanied by other resistance sites. RtT184S/A/I/L, rtS202G, rtM/V207I existed only in the multi-site resistance pattern.The genotype C was more prone to mutation in the shared pathway, and the mutation of the resistance pathways had no correlation with the patients’ HBeAg status.Conclusion The HBV genotypes in Shenzhen are mainly genotype B. Genotype C has a higher incidence of resistance mutation than genotype B, and is more likely to mutate in the shared pathway.

Key words: HBV, Drug resistance, Mutation, Genotype